Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Smart algorithm aims to predict prediabetes before it starts

NCT ID NCT06195566

Knowledge-focused Sponsor: Jelizaveta Sokolovska Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tested a new computer algorithm that uses data from wearable sensors and food diaries to predict a person's real-time risk of developing prediabetes. 77 overweight or obese adults wore glucose monitors and fitness trackers for 4 months. The goal was to collect data to improve the algorithm, not to treat or prevent the condition.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

77 people

The number who actually took part.

Started

Jan 2024

Finished

Sep 2025

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

Study population will be selected mainly in primary care clinic - endocrinologists, general practitioners will be informed about the study. Informative materials about the study will be prepared, which will contain the contact information (e-mail, phone number) using which the potential participant will be able to apply for the study. In addition, it is possible to invite participants to the research using public media (TV, radio, internet), social networks and the homepage of the University of Latvia. Initially, potential participants will be informed about the purpose, the progress of the study by phone or e-mail. If potential individuals willing to participate, more detailed information and signing of informed consent forms will take place during the screening visit.

Ages

18 to 65 years

Sex

Anyone

Healthy volunteers

Accepted

You do not need to have the condition being studied to take part.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Healthy adult volunteers (age ≥ 18 years old); * Overweight (BMI 25 - 29.9 kg/m2) and obese grade I individuals (with BMI 30 - 34.9 kg/m2); * Written consent of the participant after being informed; * Ownership of a smartphone running Android or iOS. Exclusion Criteria: * Non-compliance; * Ongoing treatment with immunosuppressive and/or anti-inflammatory medications (NSAIDs, glucocorticoids, chemotherapy, biologicals); * Ongoing treatment with glucose lowering drugs, except if anti-diabetic medication has not been stopped - for metformin one month, for GLP-1 RA, tirzepatide - two months prior enrolment; * Presence of autoimmune and/or inflammatory disease (autoimmune thyroid disease, psoriasis, inflammatory bowel disease); * Skin conditions hindering application of continuous glucose monitoring systems; * Diabetes or prediabetes as diagnosed by ADA/WHO criteria according to fasting glucose and/or HbA1c; * High risk alcohol consumption - according to NIAAA - National Institute on Alcohol Abuse and Alcoholism (for men - more than 4 drinks on any day or more than 14 drinks per week; for women - more than 3 drinks on any day or more than 7 drinks per week); * Factors otherwise limiting the participation in the study according to the judgement of the investigator; * Pregnancy or intention to get pregnant during the study timeline.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Body weight are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

Body Weight Obesity obesity disorder Overweight prediabetes syndrome

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Body weight Life style, healthy Overweight or obesity Prediabetic state

Contacts and locations

Locations

  • University of Latvia, Faculty of Medicine

    Riga, Latvia

More trials for these conditions

Other studies related to the condition(s) this trial covers.